Galenea
790 Memorial Drive, Suite 202
Cambridge
Massachusetts
02139
United States
Tel: 617-374-1010
Fax: 617-374-1320
Website: http://www.galenea.com/
Email: Info@Galenea.com
18 articles about Galenea
-
Galenea Awarded $3 Million National Institutes of Health (NIH) Grant to Develop Translational EEG Biomarkers for Schizophrenia
9/6/2012
-
Galenea and CHDI Foundation Announce Extension and Expansion of Huntington's Disease Collaboration
8/9/2012
-
Timothy A. Ryan, PhD Joins Galenea's Scientific Advisory Board
7/16/2012
-
Galenea and Eisai Company, Ltd. Enter into Research Collaboration to Develop Synaptic Modulators for Neurodegenerative Diseases
7/10/2012
-
Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
4/26/2012
-
Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function
10/11/2011
-
Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function
10/6/2011
-
Galenea Awarded Two SBIR Grants to Advance Innovative Approaches for the Discovery and Development of Effective Treatments for Schizophrenia
9/28/2011
-
Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease
9/6/2011
-
Galenea Awarded $4.5 Million Grant for Advancement of Innovative Synaptic Transmission Screen
10/15/2010
-
Galenea and Otsuka Pharmaceutical Co., Ltd. Announce Second Extension to Schizophrenia Research Collaboration
12/2/2009
-
Galenea Awarded RC1 Challenge Grant to Develop Predictive In Vivo Models of Cognition
10/6/2009
-
Galenea and Organix Inc. Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
10/28/2008
-
Galenea and Otsuka Pharmaceutical Co., Ltd. Extend & Expand Schizophrenia Research Collaboration Worth $75 Million
10/6/2008
-
Galenea Appoints Mark Benjamin as Chief Executive Officer
5/21/2007
-
Galenea To Focus On Development Of CNS Drugs
4/7/2006
-
Nastech Pharmaceutical Company Inc. Acquires RNAi Therapeutics Program Targeting Influenza From Galenea
2/23/2006
-
SBIR Awarded Phase I Galenea To Develop siRNA Products For Prevention And Treatment Of Influenza Infection
11/17/2005